CCN2 and Hepatic fibrosis: The significance of the YAP downstream CTGF [4] as a potential therapeutic target for liver fibrosis has been demonstrated in several studies employing siRNA-based knockdown of CTGF, which resulted in prevention or inhibition of liver fibrosis in rodents [8, 9].